This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

A Case for Two Life-Science REITs

NEW YORK ( TheStreet) - Real estate investment trusts in the life-sciences sector are buoyed by sustainable revenue from large drug and medical-research companies, and these companies, in turn, are sustained by new advances and drug approvals from the Food and Drug Administration.

The increase in FDA approvals has created a need for space for scientific research, a boon for life-science REITs and something investors should consider.

Alexandria Real Estate Equities (ARE) and BioMed Realty Trust (BMR) are the only two pure-play life-science REITs with a combined market capitalization of around $9 billion.

A few weeks ago, I wrote about Alexandria, the oldest of the life-science REITs that went public in 1997. BioMed Realty went public in 2004 and has a similar investment model with 95 properties and assets of around $5 billion.

Life-science REITs tend to own properties near big pharmaceutical companies close to major universities. Hot spots include San Francisco, Boston, and San Diego. Alexandria is focused on companies developing treatments for major diseases, including cancer, while BioMed is investing in university research and development centers.

In June, BioMed completed its acquisition of Wexford Science and Technology for $672 million. Wexford owns 11 properties in eight markets with around 1.6 million square feet of space (86% leased).

The life-science sector is a newer REIT category that is a hybrid between office and health care. Leases are stable because lab space is scarce. Larger health care REITs such as HCP Inc. (HCP) and Health Care REIT (HCN) own life-science properties, but Alexandria and BioMed are the only two REITs that focus on that niche.

As FDA-related approvals accelerate, Alexandria and BioMed benefit from improved credit quality as the larger drug companies have produced higher risk-adjusted returns. The Amex Biotech Index outperformed the S&P 500 in the first quarter (18% to 10%) and is up 74% since the start of 2012.

BioMed has performed the best since the end of the recession with a total return of 48.22%, compared with 16.83% for Alexandria. Both have moved back up over the last 30 days returning around 8.5% each. Total return includes stock price appreciation and dividend payouts.

BioMed has a dividend yield of 4.42%, and Alexandria's is 3.71%. Both REITs are investment-grade rated by S&P (BBB-) and they are trading at fair valuation ranges.

Of the two, I like BioMed since the shares are trading at a lower earnings multiple of around 14.3x, and I believe the Wexford deal provides BioMed with a new line of business in the university research sector where the combined company will be able to mine the new opportunities.

At the time of publication the author had no position in any of the stocks mentioned.

This article was written by an independent contributor, separate from TheStreet's regular news coverage.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $109.49 -1.20%
FB $92.40 0.00%
GOOG $638.31 -0.63%
TSLA $226.00 -2.60%
YHOO $32.35 1.50%


Chart of I:DJI
DOW 17,050.75 +138.46 0.82%
S&P 500 1,995.83 +15.91 0.80%
NASDAQ 4,810.7880 +19.6360 0.41%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs